How Does Erythromycin Work?

Erythromycin works by binding to the large (50S) subunit of the bacterial ribosome and stalling the production of bacterial proteins, which stops bacteria from growing and multiplying. Because human cells build proteins on structurally different ribosomes, the drug can halt bacterial growth while leaving human cells largely unaffected. It is generally bacteriostatic, meaning the body's immune system finishes the job of clearing the infection.

How Erythromycin Works, in Plain Language

Every bacterium depends on ribosomes, tiny molecular machines that read genetic instructions (messenger RNA) and link amino acids together into proteins. As a new protein is built, it threads out of the ribosome through a narrow channel called the exit tunnel.

Erythromycin lodges itself inside that tunnel, close to where amino acids are joined. For many proteins, the growing chain soon bumps into the drug and the ribosome stalls. Without a steady supply of essential proteins, the bacterium cannot grow or divide. The infection stops spreading, and white blood cells and antibodies remove the bacteria that remain.

Human cells also have ribosomes, but they are built differently enough that erythromycin barely sticks to them. That difference is what makes the drug selectively toxic to bacteria.

The Binding Site: 23S rRNA in the 50S Subunit

Bacteria have 70S ribosomes made of a small 30S subunit and a large 50S subunit. Erythromycin binds almost entirely to RNA rather than protein: specifically to domain V of the 23S ribosomal RNA in the 50S subunit. Crystal structures place the drug at the upper part of the nascent peptide exit tunnel, a few amino acids' distance from the peptidyl transferase center (PTC), where peptide bonds are formed.

The key contacts involve the adenine residues A2058 and A2059 (E. coli numbering). The desosamine sugar of erythromycin interacts closely with A2058, and the 14-membered lactone ring lies flat against the tunnel wall. Ribosomal proteins L4 and L22 line nearby parts of the tunnel, which is why changes in these proteins can also affect susceptibility. Clindamycin and streptogramin B antibiotics bind overlapping sites, which explains the cross-resistance described below.

Context-Specific Translation Arrest

For decades, erythromycin was described as a simple "plug" that blocks the tunnel and stops all protein synthesis, or as a drug that prevents translocation. Structural and ribosome-profiling research has refined that picture considerably:

• The tunnel is narrowed, not sealed. Some nascent peptides slip past the bound drug and are fully synthesized, so protein synthesis is inhibited selectively rather than globally.
• Arrest depends on the peptide sequence. The ribosome tends to stall when particular amino-acid motifs occupy the PTC while the drug sits in the tunnel; motifs containing positively charged residues are classic examples. The drug alters the PTC's ability to form certain peptide bonds.
• Early drop-off. Some short peptidyl-tRNAs dissociate from the ribosome prematurely, which also depletes the pool of usable tRNA.

This context specificity has a practical consequence: bacteria exploit it to sense the drug. Many inducible erm resistance genes are preceded by a short leader peptide whose translation stalls only when a macrolide is bound; the stall unmasks the erm gene and switches resistance on. (For the history of how this understanding developed, see the history of erythromycin.)

Bacteriostatic or Bactericidal?

Erythromycin is generally bacteriostatic: it halts bacterial growth rather than killing directly. Against highly susceptible organisms, such as some Streptococcus pyogenes and Streptococcus pneumoniae strains, or at higher concentrations, it can be bactericidal. In practice, this means an intact immune response matters, and erythromycin is not a first choice where rapid bactericidal activity is essential (for example, endocarditis or meningitis, where it also penetrates the cerebrospinal fluid poorly).

Why Erythromycin Does Not Harm Human Cells

The selective toxicity of erythromycin rests on differences between bacterial and human ribosomes:

• 70S versus 80S. Human cytoplasmic ribosomes are 80S particles (60S + 40S subunits) with different rRNA sequences and structure from bacterial 70S ribosomes.
• One nucleotide makes a large difference. At the position corresponding to bacterial A2058, eukaryotic cytoplasmic rRNA has a guanine. That single change greatly reduces macrolide binding. Tellingly, the main bacterial resistance mechanism (methylation of A2058) works the same way, by disrupting this exact contact.
• Mitochondrial ribosomes: the caveat. Mitochondria descend from bacteria and carry their own ribosomes, which resemble bacterial ones more closely. Macrolides can inhibit mitochondrial translation in laboratory systems, but at usual clinical concentrations the effect is limited. Erythromycin's main toxicities in people, such as gastrointestinal upset, QT prolongation, CYP3A4 drug interactions and, rarely, reversible hearing loss at high doses, are not primarily explained by ribosome inhibition.

Time-Dependent Pharmacodynamics

Erythromycin's activity depends mainly on how long drug concentrations at the infection site remain above the minimum inhibitory concentration (MIC), rather than on peak levels. Combined with a short half-life, this is why it is dosed several times a day (for example, every 6 hours) rather than once daily. Missing doses therefore matters more than with long-acting macrolides such as azithromycin. Dosing regimens are covered in the dosage guide.

Spectrum of Activity

Erythromycin is a relatively narrow-spectrum antibiotic aimed at gram-positive cocci, a handful of gram-negative organisms, and atypical pathogens that live inside cells. Susceptibility varies widely by region, so laboratory testing guides definitive therapy. A more detailed organism list is on the basics page.

Erythromycin and MRSA

There is no recommended erythromycin dose for methicillin-resistant Staphylococcus aureus (MRSA). Most MRSA isolates carry erm or msr resistance genes, and even strains that test susceptible can develop resistance during therapy. MRSA treatment should be selected by a clinician using susceptibility results.

Resistance Mechanisms

• Target methylation (erm genes). Erm methyltransferases add methyl groups to A2058 of the 23S rRNA, blocking macrolide binding. Because clindamycin and streptogramin B share the site, this produces the MLS_B phenotype (macrolide–lincosamide–streptogramin B resistance). Expression can be constitutive or inducible.
• Inducible clindamycin resistance and the D-test. An isolate with inducible erm can appear erythromycin-resistant but clindamycin-susceptible. Placing an erythromycin disk near a clindamycin disk reveals the problem: erythromycin induces methylation, flattening the clindamycin inhibition zone into a "D" shape. A positive D-test means clindamycin may fail.
• Efflux (mef and msr genes). mef(A)/mef(E) pumps in streptococci export 14- and 15-membered macrolides (the M phenotype), usually giving lower-level resistance with preserved clindamycin activity. msr(A) in staphylococci confers resistance to macrolides and streptogramin B.
• Ribosomal mutations. Point mutations at A2058 or A2059 in 23S rRNA (important in Mycoplasma pneumoniae and Helicobacter pylori) and alterations in ribosomal proteins L4 and L22.
• Drug inactivation. Esterases and phosphotransferases that modify the macrolide, mainly in gram-negative bacteria.

Cross-resistance with clarithromycin and azithromycin is generally complete; see the macrolide class overview for how the drugs compare.

Non-Antibiotic Effects

Motilin Receptor Agonism (Prokinetic Effect)

Erythromycin structurally mimics motilin, a gut hormone that triggers the strong "housekeeping" contractions of the fasting stomach and small intestine. By activating motilin receptors on gastrointestinal smooth muscle and enteric nerves, erythromycin speeds gastric emptying. This is the basis for its off-label use in gastroparesis and before endoscopy for upper gastrointestinal bleeding, at doses below those used for infection. The same mechanism explains why cramps, nausea and diarrhea are so common. The effect diminishes with continued use (tachyphylaxis) as receptors downregulate.

Anti-Inflammatory and Immunomodulatory Effects

Long-term, low-dose macrolides have effects that go beyond killing bacteria: they reduce neutrophil recruitment and inflammatory cytokine release, lessen airway mucus hypersecretion, and interfere with Pseudomonas biofilm and quorum-sensing signaling at concentrations below the MIC. The landmark example is diffuse panbronchiolitis, a progressive airway disease described mainly in East Asia, whose prognosis improved dramatically after low-dose erythromycin became standard therapy in Japan. Newer macrolides, particularly azithromycin, are now more often used for long-term anti-inflammatory therapy in conditions such as bronchiectasis.

Pharmacokinetics in Brief

• Acid lability. Erythromycin base is degraded by stomach acid into inactive products. This is why it is given as enteric-coated tablets or as acid-stable salts and esters: stearate, ethylsuccinate and estolate. About 400 mg of ethylsuccinate provides activity similar to 250 mg of base.
• Distribution. It penetrates most tissues and enters phagocytes well, but reaches the cerebrospinal fluid poorly. It crosses the placenta and passes into breast milk.
• Half-life. About 1.5–2 hours in adults with normal function; longer in severe kidney failure.
• Metabolism. Metabolized in the liver by CYP3A4, which it also strongly inhibits. This drives many clinically important drug interactions.
• Excretion. Mainly concentrated and excreted in bile; only a small fraction of an oral dose appears unchanged in urine. It is not substantially removed by dialysis.

Frequently Asked Questions

References

1. U.S. National Library of Medicine. DailyMed: Erythromycin product labeling (Ery-Tab, Erythrocin Stearate, E.E.S., EryPed). https://dailymed.nlm.nih.gov/
2. Vázquez-Laslop N, Mankin AS. How macrolide antibiotics work. Trends in Biochemical Sciences. 2018;43(9):668–684.
3. Schlünzen F, et al. Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria. Nature. 2001;413:814–821.
4. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrobial Agents and Chemotherapy. 1991;35(7):1267–1272.
5. Clinical and Laboratory Standards Institute (CLSI). M100: Performance Standards for Antimicrobial Susceptibility Testing (current edition), inducible clindamycin resistance testing.
6. Camilleri M, et al. ACG Clinical Guideline: Gastroparesis. American Journal of Gastroenterology. 2022;117(8):1197–1220.
7. Kudoh S, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. American Journal of Respiratory and Critical Care Medicine. 1998;157(6):1829–1832.

Related Topics